Vaccine-Associated Anterior Uveitis
Vaccines · 02.08.2026 · 14 (8) · 672
DOI: 10.3390/vaccines14080672 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Vaccines, online erschienen am 02.08.2026. Verfasst von Seyyedehfatemeh Ghalibafan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology and Visual Sciences, University of Illinois Chicago, Chicago, IL 60612, USA. Die Arbeit nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NEI NIH HHS, Research to Prevent Blindness, NIH HHS.
Abstract (Originalsprache)
Vaccine-associated anterior uveitis (VAAU) is an uncommon ocular inflammatory phenotype reported after several vaccine platforms. It describes anterior segment inflammation occurring after vaccination when infectious, autoimmune, idiopathic, medication-related, and other possible causes have been reasonably excluded. The current literature indicates that post-vaccination uveitis is rare relative to the scale of immunization, although anterior uveitis is frequently reported among post-vaccination ocular inflammatory events. Evidence remains limited by reliance on case reports, case series, retrospective cohorts, and passive surveillance data, which restricts precise incidence estimation and causal interpretation. Accordingly, the available evidence primarily supports a temporal association rather than a confirmed causal relationship. Proposed mechanisms include innate immune activation, molecular mimicry, adjuvant- or formulation-related immune stimulation, bystander activation, delayed-type hypersensitivity, and host susceptibility related to prior uveitis, autoimmune disease, immune dysregulation, or genetic predisposition. Clinically, VAAU may present with redness, pain, photophobia, blurred vision, anterior chamber cells and flare, keratic precipitates, posterior synechiae, elevated intraocular pressure, vitritis, or cystoid macular edema. Most cases described in the literature are mild to moderate and improve with topical corticosteroids and cycloplegic therapy, whereas recurrent, severe, or treatment-intensive courses have been reported mainly in predisposed individuals. Future work should emphasize active surveillance, standardized phenotype-specific reporting, harmonized case definitions, and mechanistic studies to better define risk, recurrence patterns, and causality. Careful interpretation of suspected cases can support accurate diagnosis, patient counseling, and vaccine-safety monitoring without undermining clinically indicated immunization.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ophthalmology and Visual Sciences, University of Illinois Chicago, Chicago, IL 60612, USA.
- Department of Ophthalmology, Loyola University Medical Center, Maywood, IL 60153, USA.
ORCID-Profile: Seyyedehfatemeh Ghalibafan, Hajirah N Saeed
Förderung
- NEI NIH HHS
- Research to Prevent Blindness
- NIH HHS
- National Institutes of Health
Zitieren
APA
Ghalibafan, S., Oraei, M., Ashraf, M., Djalilian, A. R., Bhat, P., & Saeed, H. N. (2026). Vaccine-Associated Anterior Uveitis. Vaccines, 14(8), 672. https://doi.org/10.3390/vaccines14080672
Vancouver
Ghalibafan S, Oraei M, Ashraf M, Djalilian AR, Bhat P, Saeed HN. Vaccine-Associated Anterior Uveitis. Vaccines. 2026;14(8):672. doi:10.3390/vaccines14080672
BibTeX
@article{Ghalibafan2026,
author = {Ghalibafan, Seyyedehfatemeh and Oraei, Mona and Ashraf, Mohammadali and Djalilian, Ali R and Bhat, Pooja and Saeed, Hajirah N},
title = {Vaccine-Associated Anterior Uveitis},
journal = {Vaccines},
year = {2026},
volume = {14},
number = {8},
pages = {672},
doi = {10.3390/vaccines14080672}
}
EUVIMED